ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.

Transl Lung Cancer Res · 2022 · PMC9742620 · PMID 36519016

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Crizotinib reduced the metastatic load although this decrease did not reach statistical significance compared to the control group ( Figure 3E ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.